Aptamers are oligonucleotides evolved in vitro or in nature to bind target ligands with high affinity and specificity. They are emerging as powerful tools in the fields of therapeutics, drug development, target validation and diagnostics. Aptamers are attractive alternatives to antibody-and small-moleculebased therapeutics owing to their stability, low toxicity, low immunogenicity and improved safety. With the recent approval of the first aptamer drug Macugen by the US FDA, there is great impetus to develop therapeutic aptamers that can target a wide array of disease states. The recent demonstration that aptamer activity can be reversed by the administration of a simple antidote greatly enhances the potential value of aptamers as therapeutic agents.
Introduction
Small structured single-stranded RNAs or DNAs, also known as aptamers, are attractive and viable alternatives to small-molecule and antibody-based therapy. As a member of the family of emergent RNA therapeutic agents (Table 1) , it is unique in that it acts to disrupt at the protein level and not at the gene level. Aptamers are evolved by means of a method called SELEX (systematic evolution of ligands by exponential enrichment) to specifically recognize and tightly bind their cognate ligands by means of well-defined complementary threedimensional structures. SELEX is an iterative in vitro selection process consisting of two sequential steps (selection and amplification) that can efficiently reduce a complex library of nucleic acids with randomized sequences (complexity B10
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) to a minimized subset of one or more sequences that bind tightly to the target of choice. Typically, dissociation constants (Kd's) for these aptamer-target complexes are in the high pico-molar to low nano-molar range. A number of functionally exciting RNA aptamers have been selected against a wide range of targets, both protein and nonprotein, through SELEX.
1,2
Aptamers may be superior to antibodies for certain therapeutic applications Aptamers achieve their tight binding and specificity by adapting precise three-dimensional structures upon
In brief Progress
The stability and bioavailability of aptamers have been improved. The first aptamer drug has been approved by the US Food and Drug Administration (FDA) and additional aptamers are in the clinical pipeline. Methods to regulate aptamer activity have been developed. Functional aptamers against intracellular targets are being developed. Combinatorial RNA therapies for HIV/AIDS may have potential for stem cell based gene therapy. Creative uses of aptamers to deliver, enhance and modulate the activity of other therapeutic molecules are being explored.
Prospects
Aptamers may be superior to antibodies for certain therapies. Aptamer-antidote pairs as safe and highly regulatable drugs may soon be realized. Improved expression vectors for intracellular targets will advance aptamers as antiHIV infectivity agents. Combinatorial RNA therapies that include ribozyme, aptamer and siRNA will advance. More aptamers that can deliver, modulate and enhance small interfering RNA (siRNAs) as therapeutics will be increasingly used. Further advances in selection methods will provide aptamers against difficult to purify or unstable protein targets (such as membrane proteins). Intracellular delivery of aptamers that does not rely on expression vectors will be realized. Agonistic aptamers will be therapeutically beneficial.
binding the target ligand and essentially becoming encapsulated by the ligand. The target ligand thus becomes part of an aptamer's intrinsic structure. 3 The importance of the three-dimensional, globular structure of aptamers to their biological activities clearly distinguishes them from antisense oligonucleotides and ribozymes, which are linear and act to disrupt the expression of proteins at the mRNA level via traditional hydrogen bond interactions. Because of their tight binding properties, and because the surface features of aptamer targets frequently correspond to functionally relevant parts of the protein target, aptamers can be potent biological antagonists. This has been borne out by the number of inhibitory aptamers generated and studied in vitro, in cell culture, and in a few cases, animal studies ( Figure 1 ).
Aptamers are highly attractive alternatives to monoclonal antibodies in therapeutics because they possess the same, if not better, positive attributes of high affinity and exquisite specificity for cognate ligands. At the same time, aptamers have the advantage that they can be chemically modified with relative ease to improve their Figure 1 Aptamers have been generated against a broad array of ligands. Aptamers rely on their molecular shape complementarity to bind ligands with high affinity and exquisite specificity. As a result, the breadth of clinical indications for which aptamers may be used as therapeutic agents is quite impressive. Aptamer stability and bioavailability have been improved
The first generation of aptamers for therapeutics was severely limited by nuclease sensitivity, poor bioavailability, fast renal clearance and limited cellular uptake. These limitations have been largely overcome and the current crop of aptamers is more robust. RNA aptamers prepared with 2 0 -Fluoro-or 2 0 -amino pyrimidines or 2 0 -O-methyl nucleotides are highly nuclease resistant. 4 A dT-cap at the 3 0 -end can further inhibit degradation. To enhance both metabolic stability and nuclease resistance, unnatural L-nucleotides have been incorporated into aptamers, which are termed 'Spiegelmers.' 5 Although the small size of aptamers (5-25 kDa) results in their facile penetration of tissues, this also translates into their fast renal clearance. To retard clearance and improve bioavailability, a cholesterol or polyethylene glycol moiety can be conjugated to one end of the aptamer. 6, 7 Still, bioavailability may best be achieved not by making the aptamer drug circulate longer in the system but by increasing its avidity (binding capacity or apparent affinity for its target), which can be realized by multimerizing the aptamers in a controlled fashion. 8 The development of useful therapeutics requires testing in animals before human trials can be carried out, and aptamer development may stall if crossreactivity of the selected human aptamer sequence with the animal model of choice is poor. To overcome this possible limitation, SELEX strategies that 'toggle' selection rounds between the human protein and a corresponding animal protein (if available) have been developed. 1 This predisposes the selection of aptamers that can recognize a common, conserved structure between the human and animal target ligands.
The first aptamer drug has gained FDA approval and additional aptamers are in the clinical pipeline At this time Macugen (Pegaptanib sodium) is the only approved aptamer drug as yet. Macugen was developed for the treatment of wet-age-related macular degeneration (AMD), an eye disease that can lead to adult blindness. The pegylated, nuclease-stabilized aptamer acts as a selective antagonist of vascular endothelial growth factor (VEGF 165 ) by binding at the heparinbinding domain. 9 VEGF plays a crucial role in angiogenesis and thus in cancer as well as in AMD, where its levels are elevated. Macugen has been shown to retard vision loss and is presently in clinical trials for diabetic macular edema and retinal vein occlusion.
Other aptamers and oligonucleotide-based drug candidates in the clinical development phase include transcription factor decoys and aptamers against thrombin, Factor IXa and nucleolin (Table 2) . Transcriptional decoys are small-structured RNAs or double-stranded DNAs containing the consensus binding sequence of a specific transcription factor. When a decoy occupies its target factor's binding site, the protein is prevented from binding to the promoter regions of target genes, leading to subsequent inhibition of gene expression. Anesiva (San Francisco, CA, USA) has been actively developing transcription factor decoys for therapeutics. The E2F decoy Edifoligide was shown to disrupt E2F-mediated cell regulation, which plays a role in cardiovascular diseases such as intimal hyperplasia and atherosclerosis. Although results from the Phase I/II clinical trials were promising, further testing indicated that Edifoligide was no more effective than placebo in preventing vein graft failure 1 year after coronary artery bypass grafting (CABG) surgery. [10] [11] [12] Whether the decoy will have any delayed beneficial effects remains to be determined. 
RNA aptamers NS Que-Gewirth and BA Sullenger
The other transcriptional decoy in clinical trials is specific for nuclear factor (NF-kB).
10,11 NF-kB is an important modulator of the inflammatory response as well as other aspects of cell regulation. By mimicking the NF-kB binding sequence on the chromosomal DNA, the decoy Avrina inhibits the production of several proinflammatory cytokines. The decoy has been tested in several arthritis models as well as in endotoxin-induced models of liver failure and septic lung in mice. [13] [14] [15] Currently, Avrina is in Phase I/II trials for treatment of mild-to-moderate atopic dermatitis. In addition, a phosphorothioated NF-kB decoy was recently tested in a murine inflammatory bowel disease model. 16 A number of aptamers that target coagulation factors (thrombin, Factor IXa, Factor VIIa and Factor XII) have been generated, and those specific for thrombin and Factor IXa are presently in the early stages of clinical development. 17, 18 Thrombin is a serine protease that cleaves fibrinogen into fibrin, resulting in the formation of a fibrin clot. In addition, it is also a powerful stimulator of platelets. A number of RNA as well as DNA aptamers have been reported that bind to the fibrinogen binding site (Exosite I) or the heparin binding site (Exosite II) of thrombin. 1, 17 Among these, AR-C183(Archemix, Cambridge, MA, USA) and NU172 (formerly ARC2172) are in the clinical pipeline. The DNA aptamer ARC183, which binds to the fibrinogen binding site, was shown to prolong clotting times in plasma and showed potential in a canine cardiopulmonary bypass model as well as in a sheep anticoagulation model. However, Arc183 exhibited a suboptimal dosing profile in Phase 1 clinical trials for CABG surgery.
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Aptamer NU172, a short-acting, thrombin antagonist that prevents fibrin generation, is in pre-clinical development for acute cardiovascular procedures. 19, 20 Although the clotting pathway has been a major focus of aptamer development, a number of aptamers and oligonucleotide-based molecules have also been described for anticancer therapies. The aptamer AS1411 (Antisoma, London, UK) is currently in Phase I clinical trials for renal and lung cancer. 21 ,22 AS1411, formerly AGRO100, is an unmodified 26-mer oligodeoxynucleotide that belongs to a subgroup of aptamers collectively known as guanine-rich oligonucleotides (GROs). GROs are single-stranded DNAs with characteristic quadruplex structures that are stabilized by G-quartets. The anticancer effects of AS1411 arise from binding to nucleolin, a protein uniquely expressed on the surface of tumor cells, as well as by blocking NF-kB activation and signaling. 23 The studies with AS1411 represent the first human clinical testing of nucleic acid aptamers for the treatment of cancer.
Other aptamers that have advanced to tests in animal models include the anti-platelet-derived growth factor (PDGF)-B aptamer ARC127 (Archemix, Cambridge, MA, USA) and antihemagglutinin (HA) aptamer A22. ARC127 binds to PDGF-B and was previously shown to inhibit the interaction of PDGF with its receptor in rats suffering from renal disease or colon carcinomas. Recently, it was found to have potential in treating proliferative retinopathies, based on intraocular injection of the aptamer in rho/PDGF-B mice, which are extremely aggressive models of this disease. 24 The DNA aptamer A22 that confers protection against the Influenza A virus by binding to HA is also being tested in both tissue cultures and mouse models, where it was found to be as effective as the flu drug Zanamivir. 25 A list of older therapeutically relevant aptamers is shown in Figure 1 . 1 [26] [27] [28] The best-known treatment before these was photodynamic therapy with Visudyne, which averaged at $3000/dose. 26, 27 Clinical studies have shown that Lucentis treatment can improve visual acuity, but only if a monthly injection is followed and follow-up treatment to prevent the disease from recurring is expected to be indefinite. 28 With less frequent Lucentis injection, visual loss was retarded but no visual gains were observed, similar to what Macugen treatment affords. There is lingering skepticism about the long-term safety of Lucentis because it is an antibody and particularly because its 'parent' antibody, Avastin, has been shown to increase risk of stroke and heart attack. Arguments have been made that Lucentis presents a minimized possibility for serious side effects because of its smaller size and the localized delivery. Still, Macugen, which is specific for the VEGF 165 isoform, may have a better long-term safety profile than Lucentis, which binds all VEGF isoforms. 29 Thus, Macugen is now being tested in Phase IV trials as a follow-up or maintenance drug after initial gain in vision is achieved by Lucentis treatment. Complicating the comparison between Lucentis and Macugen is Avantis, which is being used off-label to treat wet AMD. Avantis can cost $50 000 annually for cancer treatment but with the small amounts needed for eye injections, dosing is expected at $17-50 per injection. 30, 31 A better picture of the efficacy and especially the safety of Macugen, Lucentis or Avantis for AMD treatment will be revealed in the next few years.
How does
Macugen therapy compare to Lucentis therapy for macular degeneration? Up until this point it has been difficult to realistically compare aptamer therapy versus antibody treatment. With Macugen and its corresponding antibody for wet AMD on the market, we can now make such a comparison, albeit a limited one. Lucentis (ranibizumab) (Genentech, San Francisco, CA, USA) is a humanized antibody fragment that inhibits VEGF and is derived from the full-length antiVEGF antibody Avastin (bevacizumab, Genentech) that was previously approved for cancer treatment. Macugen therapy requires 8-9 injections per year and costs about $1000 per injection. In contrast, Lucentis costs approximately twice that per injection ($1950/dose), and a gain in visual acuity, which gives Lucentis an edge over Macugen, is obtained only with monthly injections.
Methods to regulate aptamer activity have been developed
A significant advance in aptamer technology is the demonstration that 'antidotes', which are short complementary sequences (antisense) to the aptamers, can reverse the inhibitory properties of aptamers (Figure 2) . The facile reversibility of aptamers with an antidote is a unique feature that is not easily achieved in antibody RNA aptamers NS Que-Gewirth and BA Sullenger therapy. The aptamer-antidote pair is a powerful concept that can find exciting uses in therapeutics, and is most applicable in settings, such as surgery, that demand the use of drugs that can be readily reversed or modulated. The 9.3t aptamer-antidote pair was shown to be efficacious in a porcine systemic anticoagulation model and a murine arterial injury model. 6 Further validation of aptamer-antidote pairs as viable replacements for heparin-protamine therapy was demonstrated in a porcine cardiopulmonary bypass surgery model. 32 As a reduction in thrombin generation and inflammation was observed compared to heparin-protamine therapy, this regimen may be particularly well suitable for patients sensitized to protamine or with heparin-induced thrombocytopenia. A derivative of the factor IXa aptamerantidote pair is currently being developed by Regado Biosciences Inc (Durham, NC, USA).
An interesting approach to regulate aptamer activity by a light trigger was introduced through the selective incorporation of photolabile nucleobases into an aptamer. [33] [34] [35] When a photolabile 'protecting' group is attached to a biological molecule to mask its biological activity, the molecule is 'caged'. Thus, when a key thymidine or guanosine residue of the DNA antithrombin aptamer was selectively substituted with the caged analogs T NPP or dG NPP (where NPP is the photolabile 2-(2-nitrophenyl)-propyl group), the modified aptamer did not bind thrombin nor inhibit a plasma clotting assay. Upon 'uncaging', the aptamer regained its ability to bind thrombin and prolong clotting, although not as well as the unmodified aptamer. Serious considerations including the sequence dependency of uncaging that may necessitate an excess of the modified aptamer, basic pH optimum (pH 11.0) for uncaging may limit the appeal of caged aptamers. 33, 34 A variant of this strategy involves an aptamer-'caged' antidote chimera. 35 The chimera is a single oligonucleotide containing both an aptamer region (antithrombin DNA aptamer) and its temporarily inactivated 'caged' antisense (antidote) region (Figure 2) . Although complete inhibition of aptamer activity was achieved upon irradiation, the chimera was only about half as active as the wild-type aptamer in a one-stage thrombin-based clotting assay.
Aptamers for intracellular targets are being developed
In contrast to antibodies that can become denatured and inactive in the reducing environment inside the cell, nucleic acid-based aptamers are predisposed to survive intracellular conditions. Thus, it is envisioned that aptamers will recognize and inhibit their intracellular cognate ligands once inside the cell, and thereby modulate gene function at the protein level. This necessitates the intracellular delivery and expression of the aptamers in their properly folded and functional forms. Currently, delivery can be achieved either through direct transfection or specific aptamer expression systems.
Aptamer expression cassettes that provide high intracellular levels of transcribed aptamers have been designed with various promoters, including RNA Pol II (CMV, Hic, Mtn), which directs the cytoplasmic export of the nascent transcript from the nucleus and RNA Pol I and Pol III (tRNAU6, H1). 36 Incorporation of functional sequences in flanking regions can be used to stabilize the aptamer constructs within the cytoplasm as well as obtain expression of tandem aptamer arrays to generate polyvalent transcripts and increase antagonism. 36 In vivo expression of aptamers have often necessitated their being expressed as chimeras such as when they are fused to tRNAs, self-cleaving ribozymes or aberrantly spliced mRNAs or embedded into U16 small nucleolar RNAs. [36] [37] [38] Because the flanking sequences in these chimeras may interfere with the proper folding of the aptamer, a strategy called 'Expression Cassette SELEX' for selecting functional chimeric tRNA-aptamer transcripts was proposed. This method, which involved generating a set of randomized flanking sequences followed by selecting for chimeric tRNAs that retained higher affinity for the target protein, was successfully demonstrated but proved to be technically complex and tedious. In order to overcome these difficulties, a 'pure' aptamer in vivo expression system was recently designed, resulting in the intracellular expression of a 'pure' and functional NK-kB aptamer. 39 A number of intracellular protein targets for antiHIV therapy have been subjected to SELEX. Aptamers are regarded as highly viable drug candidates because they present little of the notorious side effects associated with the current available treatments. 36, [40] [41] [42] [43] In addition, whereas gene therapies involving ribozymes and/or Figure 2 Aptamer activity can be reversed by an antidote. Two aptamer-antidote designs have been described. (a) The classic antisense oligonucleotide as an antidote was added to a proteinaptamer complex as illustrated by the anti-Factor IXa aptamer 9.3t. When the antidote was added, the anticoagulating effect of aptamer 9.3t was abolished and clotting parameters returned to normal. 6 (b) An aptamer-'caged' antidote chimera was designed to allow for light-triggered deactivation of a thrombin aptamer, and hence reverse the aptamer's function. 35 NPE ¼ 1-(2-nitrophenyl)ethyl.
RNA aptamers NS Que-Gewirth and BA Sullenger small interfering RNA (siRNAs) may suffer from the emergence of HIV-1-resistant mutations, an aptamerbased gene therapy may not face the same difficulty because viable aptamer-resistant HIV-1 mutants are expected to be rare. 40, 44 Numerous aptamers and RNA decoys have been selected to disrupt key stages of the viral life cycle including enzymatic function (by targeting reverse transcriptase (RT) and integrase), gene expression (targeted against Rev and Tat), viral packaging (targeted against nucleocapsid and p55
Gag proteins) and viral entry (targeted against gp120 and gp41) into the host cell (Figure 3) . 36 As intracellularly expressed antiHIV-1 RT aptamers had shown promise as antiviral agents in cell culture assays, additional RT-directed aptamers continue to be described, including those that selectively inhibit the RNaseH domain of HIV-1 RT. 45, 46 One of the more exciting antiHIV-1 aptamers reported to date is the RNA aptamer B4 that is specific for gp120 of HIV-1 strain R5. The envelope protein gp120 controls viral entry through its interaction with chemokine receptors. The aptamer B4 was found to be highly effective in neutralizing HIV-1 infectivity in human peripheral blood mononuclear cells by more than 1000-fold. 47, 48 As gp120 is a surface protein, further studies will not require intracellular expression of aptamer B4.
Thus, this may facilitate testing of an antiHIV-1 aptamer in animal models. 36 In addition, phosphorothioate oligonucleotides were recently shown to block gp120 interactions and HIV infection in vitro. 49 Other viral infections were also targeted for aptamer intervention, including those owing to hepatitis C virus (HCV), Rous sarcoma virus and Human cytomegalovirus. Aptamers have been generated against the HCV proteins Nonstructural proteins 3 (NS3) and 5B (NS5B) that are required for viral proliferation. The RNA aptamer (G9-II) specific for NS3 was found to inhibit the protease activity of NS3 in vitro and in HeLa cells. 50 HCV translational inhibitors were also obtained by selecting for RNA aptamers against the viral internal ribosome entry site, where translation starts. 51 Combinatorial RNA therapies for HIV-1 infection may have potential for stem cell-based gene therapy
The strategy of combining several RNA-based therapies -ribozyme, decoy RNA (aptamer), siRNA -is an attractive approach that exploits the best features of the individual methodologies to overcome the limitations of Figure 3 RNA therapeutics against viral infection. Aptamers, ribozymes and siRNA can be used individually or in combination to contain viral infection by disrupting key points in the viral life cycle. All of these agents rely on proper colocalization with their targets. Ribozymes and siRNA may suffer from off-target effects as well as the outgrown of HIV-1-resistant mutations, which may make them less efficient for long-term HIV inhibition. As such their combination with other therapies may be preferred so as to prevent the emergence of resistant strains and help achieve a synergistic effect against viral infection.
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RNA aptamers NS Que-Gewirth and BA Sullenger each. Specific combinations may be tailored to enable each of these inhibitors to target distinct phases of the viral cell cycle, reduce the possibility of viral escape mutants and possibly obtain a synergized level of inhibition. 38 Significant advances in improving lentiviralbased vectors have been instrumental in these studies and will be instrumental in the realization of an RNAbased antiviral approach to long-term gene therapy against HIV-1 infection. [52] [53] [54] A lentiviral-based construct that harbored both a CCR5 ribozyme that downregulates HIV-1 cell surface coreceptor, and a U16TAR decoy, which inhibits viral Tat-activated transcription, was shown provide a high degree of resistance against HIV-1 in both primary and CD34(+)-derived monocytes. 38, 55 A similar effect was obtained with a combinatorial construct harboring an antiCCR5 ribozyme (as well as ribozymes targeted to viral mRNAs coding for tat, rev and env proteins), a rev RNA decoy, and an siRNA directed against a sequence common to rev and tat mRNAs. 56 Recently, Rossi described a triple-element combinatorial therapeutic RNA vector that harbors: (1) a U6 Pol III promoterdriven short hairpin RNA specific for rev and tat mRNAs; (2) a U6 transcribed nucleolar-localizing TAR RNA decoy; and (3) a VA1-derived Pol III cassette that expresses an antiCCR5 ribozyme. 55 HIV replication was inhibited by this 'triple-threat' approach and illustrates further the feasibility of combinatorial RNA-based gene therapy for HIV infection (Figure 3 ). In addition, these results highlight the potential of inhibitory RNAs in stem cell-based gene therapy for HIV/AIDS. 54 Creative uses of aptamers to deliver, enhance and modulate the activity of other therapeutic molecules are being explored
The issue of efficient and tissue-specific delivery, as well as enhancing and modulating biological activity is not unique to aptamers. A number of exciting reports from three research groups have recently illustrated the potential of aptamers to deliver other therapeutic agents including nanoparticle-encapsulated drugs, siRNAs and toxins in a cell-type-specific manner. [57] [58] [59] [60] [61] By conjugating a toxic or gene regulatory agent to a tight-binding aptamer that is specific for prostate-specific membrane antigen (PSMA), these groups have demonstrated a specialized and specific-targeting of prostate cancer cells. As PSMA is a receptor that is overexpressed only on the cell surface of prostate cancer cells and vascular endothelium, cell-type-specific delivery was achieved.
Langer's group designed and successfully used nanoparticle:aptamer conjugates to deliver the nanoparticle encapsulated drug doxetacel to prostate cells. Furthermore, after a single intratumoral injection of the conjugate, complete tumor reduction was observed in LNCAP xenograft nude mice with 100% survival. 58 Two groups also described the preparation of aptamer:siRNA conjugates composed of the antiPSMA aptamer that was joined to an siRNA either covalently (polio-like Kinase 1 (PLK1), BCL2) or noncovalently (glyceraldehyde-3-phosphate dehydrogenase, Lamin A/C). [60] [61] [62] Effective internalization of the aptamer-siRNA complex/chimera into the cytosol was observed, followed by Dicer processing of the complex/chimera to release the functional siRNA. More importantly, the PSMA aptamer-PLKi-siRNA was found to promote tumor regression in a mouse xenograft model. 61 The ribosomal toxin gelonin was also delivered in similar specific fashion to prostate tumor cells. 59 This aptamer:toxin conjugate promoted uptake into target cells and also decreased the toxicity of gelonin in nontarget cells.
Currently aptamers are also being exploited to regulate gene expression directly or indirectly. Recently, a theophylline-binding aptamer was used to modulate siRNA activity in HEK293 cells. With the adjuvant siRNA, the aptamer was thus transformed into a promising tool to post-transcriptionally regulate expression in mammalian cells. 63 Intracellularly expressed aptamers were also shown to be viable alternatives to siRNA knockdown for direct regulation of gene expression. 64 Thus, it is possible that a combination of an aptamer and siRNA against a gene target may be the method of choice to maximize knockdown of protein activity.
Prospects
Expectations are great that aptamers can be competitive as therapeutic compounds, particularly when drug administration only requires local or transient delivery because then an antidote can be safely delivered to reverse the aptamer. 21 Whether an intracellular aptamerantidote pair can be generated remains to be seen but it is an attractive possibility. Aptamer technology is presently at an exciting stage where it is being creatively integrated with other RNA-based therapeutics to deliver and modulate biological activity. However, the number of candidate aptamers that can act as delivery agents for siRNA internalization needs to be increased and diversified. In addition, there remains a gap in the aptamer portfolio for membrane proteins and other targets that are difficult to purify or which are not amenable to selection. This is where advances in selection methods are going to be critical. In particular, the concept of 'complex-target' selection, where targets are not pure proteins but may include whole organisms, intact cells or human plasma, may lead to the identification of aptamers against proteins that can only be targeted in their physiological milieu. [65] [66] [67] [68] In some biological systems, agonists may be of more therapeutic importance than antagonists and we envision that agonistic aptamers will soon be realized. Furthermore, the increasing focus on the use of aptamers as tools for diagnostics, target validation and drug discovery will maximize the potential of aptamers in therapeutics. 69, 70 As for gene therapy, an efficient and targeted mode of delivery continues to be the major roadblock in achieving the full potential of RNA therapeutics as intracellular drugs. Results from a multipronged approach to HIV gene therapy that involves the combined delivery of aptamers, ribozymes and siRNAs to the cell are very promising, but their ultimate utility awaits further clinical evaluation. Two recent encouraging reports that describe a antisenseRNA-based gene therapy (VIRxSYS, Gaithersburg, MD, USA) as well as a bold antiHIV-1 ribozyme (OZ-1) experiment that combined gene therapy and stem cells emphasize the promise of RNA based, and quite possibly aptamer-based, gene therapy approaches for AIDS treatment.
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Conclusions
Aptamers are relatively new comers in the field of therapeutics. However, their advantages (low-toxicity, low-immunogenicity, more facile manufacturing processes) strongly warrant their use as alternatives to small molecule and antibody based therapies. More importantly, the fact that aptamer effects can be reversed with a simple and relatively inexpensive antidote puts them in a class beyond antibodies for therapeutics. Remarkable progress has been achieved using combinatorial approaches that include aptamers as therapeutic molecules including a new facet of aptamer functionality: as specific delivery vehicles for other therapeutics.
